Evidence map›Paper›PMID 30342059›Full record

ArticleToxicology and applied pharmacology2019

Role of ZIP8 in regulation of cisplatin sensitivity through Bcl-2.

Xiangrong Geng, Liu Liu, Kan-Jen Tsai, Zijuan Liu

Abstract read
In one paragraph

Article in Toxicology and applied pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Xiangrong GengDepartment of Biological Sciences, Oakland University, Rochester, MI 48309, USA.
Liu LiuDepartment of Biological Sciences, Oakland University, Rochester, MI 48309, USA.
Kan-Jen TsaiDepartment of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.
Zijuan LiuDepartment of Biological Sciences, Oakland University, Rochester, MI 48309, USA. Electronic address: liu2345@oakland.edu.
Oakland University · USChung Shan Medical University · TW

Funding

Role of SLC39A8 (ZIP8) in selenite transportR15ES022800 · NIEHS · OAKLAND UNIVERSITY · PI LIU, ZIJUAN · 2013 to 2015
$445k
NIEHS NIH HHS R15 ES022800
6 · The paper itself

Abstract

ZIP8 is a membrane transporter that facilitates the uptake of divalent metals (e.g., Zn, Mn, Fe, Cd) and the mineral selenite in anionic form. ZIP8 functionality has been recently reported to regulate cell proliferation, migration and cytoskeleton arrangement, exhibiting an essential role for normal physiology. In this study, we report a ZIP8 role in chemotherapy response. We show ZIP8 regulates cell sensitivity to the anti-cancer drug cisplatin. Overexpression of ZIP8 in mouse embryonic fibroblast (MEF) cells induces cisplatin sensitivity, while knockout of ZIP8 in leukemia HAP1 cells leads to cisplatin resistance. In ZIP8 altered cells and transgenic mice, we show cisplatin is not a direct ZIP8 substrate. Further studies demonstrate that ZIP8 regulates anti-apoptotic protein Bcl-2. ZIP8 overexpression decreases Bcl-2 levels in cultured cells, mice lung and liver tissue while loss of ZIP8 elevates Bcl-2 expression in HAP1 cells and liver tissue. We also observe that ZIP8 overexpression modulates cisplatin-induced cell apoptosis, manifested by the increased protein level of cleaved Caspase-3. Since Bcl-2 elevation was previously discovered to induce cisplatin drug resistance, our results suggest ZIP8 may modulate cisplatin drug responses as well as apoptosis through Bcl-2. We therefore conclude ZIP8 is a new molecule to be involved in cisplatin drug responses and is predicted as a genetic factor to be considered in cisplatin therapy.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCation Transport ProteinsCell LineCisplatinDrug Resistance, NeoplasmFibroblastsHumansMaleMice, Inbred C57BLMice, TransgenicProto-Oncogene Proteins c-bcl-2Tissue DistributionAntineoplastic AgentsBCL2 protein, humanCation Transport ProteinsCisplatinProto-Oncogene Proteins c-bcl-2SLC39A8 protein, humanSlc39a8 protein, mouseApoptosisBcl-2CisplatinDrug-resistanceTransporterZIP8

Identifiers

PMID30342059
PMCPMC6289643
OpenAlexW2897466356

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.